The MassHealth Guidelines for Medical Necessity Determination (Guidelines) are used by MassHealth's reviewing clinicians to determine the medical necessity of prior-authorization requests submitted by providers.
- This page, MassHealth Guidelines for Medical Necessity Determination for Gene Expression Profiling Tests for Breast Cancer, is offered by
MassHealth Guidelines for Medical Necessity Determination for Gene Expression Profiling Tests for Breast Cancer
Table of Contents
Guidelines for Medical Necessity Determination for Gene Expression Profiling Tests for Breast Cancer
These Guidelines for Medical Necessity Determination (Guidelines) identify the clinical information that MassHealth needs to determine medical necessity for gene expression profiling tests for breast cancer. These Guidelines are based on generally accepted standards of practice, review of the medical literature, and federal and state policies and laws applicable to Medicaid programs. Providers should consult MassHealth regulations at 130 CMR 401.000 and 450.000 and Subchapter 6 of the Independent Clinical Laboratory Manual for information about coverage, limitations, service conditions, and other prior-authorization (PA) requirements.
Providers serving members enrolled in a MassHealth-contracted accountable care partnership plan (ACPP), managed care organization (MCO), integrated care organization (ICO), senior care organization (SCO), or program of all-inclusive care for the elderly (PACE) should refer to the ACPP’s, MCO’s, ICO’s, SCO’s or PACE’s medical policies for covered services.
If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including member eligibility, other insurance, and program restrictions.